Benzinga | Aug 16, 2021 09:11AM EDT

Morgan Stanley Maintains Equal-Weight on Sarepta Therapeutics, Lowers Price Target to $90

Morgan Stanley analyst Matthew Harrison maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Equal-Weight and lowers the price target from $93 to $90.